Inaccurate Financial Forecasts
This lawsuit alleges that since November 12, 2014, Abengoa has misrepresented the liquidity of its balance sheet in corporate reports filed with the SEC and in conference calls with financial analysts.
This lawsuit alleges that, during the first half of 2015, Biogen purposefully overstated its future revenue growth, based largely on expectations for its flagship drug TECFIDERA, and that the overstated forecast artificially inflated the Biogen stock price.
This lawsuit alleges that executives at Spectranetics failed to properly warn of problems in its revenue forecasts and this failure to fully disclose these problems led to an artificially inflated stock price.
This securities fraud class action alleges that CaesarStone failed to disclose a whole series of negative news developments to investors in real time and in fact purposely kept the news from them.
This lawsuit alleges that executives at El Pollo Loco hid from investors the negative impact of rising labor and food costs and the decrease in same store traffic so that insiders could sell millions of dollars of stock at artificially inflated prices.
This lawsuit alleges that TriNet did not properly model medical and insurance costs for its workers compensation services, thereby overstating revenues and net income for the time period in question. What makes these allegations partially troubling is that the industry as a whole seemed to be adjusting costs upward at a time when the company was assuring investors it did not need to do the same.